NCT07900451 Multimodal Biomarkers Predicting Medication-Induced Adverse Effects in Children With ADHD
| NCT ID | NCT07900451 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | ADHD |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2029-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2026-08-01 with a primary completion date of 2029-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To build a multimodal model combining neuropsychological, neurophysiological, and metabolomic measures to identify biomarkers predicting MPH-induced adverse effects and their underlying mechanisms, supporting individualized risk assessment in clinical practice.
Eligibility Criteria
Inclusion Criteria: * Participants, between the ages of 6 and 16 must meet the DSM-5 criteria for ADHD. * At the time of initial evaluation, participants must exhibit a score greater than 3 on the Clinical Global Impressions scale for ADHD Severity (CGI-ADHD-S). * Cognitive assessment of participants must demonstrate a Full-Scale Intelligence Quotient (FSIQ) greater than 80. Exclusion Criteria: * Individuals with comorbid major psychiatric disorders-including autism spectrum disorder (ASD), psychotic disorders, mood disorders, or substance use disorders-will be excluded. * Individuals with major neurological conditions, such as epilepsy or other central nervous system disorders, will be excluded. * Individuals with serious systemic medical conditions, including diabetes mellitus or cardiovascular disease, will be excluded. * Individuals with any prior exposure to pharmacological treatments specifically intended for managing ADHD symptoms will be excluded.
Contact & Investigator
Susan Shur-Fen Gau, MD, PhD
STUDY DIRECTOR
Department of Psychiatry, National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT07900451 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 16 Years, studying ADHD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07900451 currently recruiting?
Yes, NCT07900451 is actively recruiting participants. Contact the research team at cyshang@ntu.edu.tw for enrollment information.
Where is the NCT07900451 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07900451 clinical trial?
NCT07900451 is sponsored by National Taiwan University Hospital. The principal investigator is Susan Shur-Fen Gau, MD, PhD at Department of Psychiatry, National Taiwan University Hospital. The trial plans to enroll 90 participants.